Probenecid And Colchicine Tablet
NDC Package 0591-5325-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Probenecid And Colchicine tablets is for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. This formulation utilizes a tablet delivery system. Marketed by Actavis Pharma, Inc., this product is identified by NDC 0591-5325 and is authorized under FDA application ANDA084279.

Identification & Billing

NDC Package Code
0591-5325-01
Package Description
100 TABLET in 1 BOTTLE, PLASTIC
Product Code
0591-5325
11-Digit Billing Format
00591532501
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 198153 - probenecid 500 MG / colchicine 0.5 MG Oral Tablet
  • RxCUI: 198153 - colchicine 0.5 MG / probenecid 500 MG Oral Tablet

Clinical Specifications

Proprietary Name
Probenecid And Colchicine
Non-Proprietary Name
Probenecid And Colchicine
Substance Name
Colchicine; Probenecid
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout.

Regulatory & Marketing

Labeler Name
Actavis Pharma, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA084279
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-01-1982
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0591-5325). Click a package code to view its specific billing and regulatory data.

0591-5325-00
14000 TABLET in 1 BAG
0591-5325-77
17148 TABLET in 1 CONTAINER

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0591-5325-01 identifies a specific commercial package of 100 tablet in 1 bottle, plastic of Probenecid And Colchicine, a human prescription drug labeled by Actavis Pharma, Inc.. This tablet is formulated for oral use and contains colchicine; probenecid as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Actavis Pharma, Inc. on October 01, 1982. The current certification is valid through December 31, 2026.

How is this Actavis Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00591532501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0591-5325-01
11-Digit CMS (5-4-2)
00591-5325-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.